ARTICLETopiramate Off-Label Use in Psychiatric DisordersBarnhorst, Amy MD; Xiong, Glen L. MDEditor(s): Janicak, Philip G. MD; Editor Author Information Dr. Barnhorst is Assistant Clinical Professor, and Dr. Xiong is Assistant Clinical Professor, Department of Psychiatry & Behavior Sciences, University of California at Davis, 2230 Stockton Blvd, Sacramento, CA 95817-1419; E-mail: [email protected]. All faculty and staff in a position to control the content of this CME activity, and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. The authors have disclosed that the use of topiramate for treatment of psychiatric disorders as discussed in this article has not been approved by the U.S. Food and Drug Administration. Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on May 31, 2013. Psychopharm Review: June 2012 - Volume 47 - Issue 6 - p 41-46 doi: 10.1097/01.PSYPHR.0000415488.63708.04 Buy CME Test Metrics © 2012 Lippincott Williams & Wilkins, Inc.